NOVAN INC (NOVN) Stock News
NASDAQ:NOVN - Nasdaq - US66988N2053 - Common Stock - Currency: USD
NOVN Latest News, Press Relases and Analysis
Verrica's Ycanth Unlikely to Face Near-Term Competition, Analyst Upgrades Stock On FDA Approval
Monday, the FDA approved Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) Ycanth (cantharidin) topical solution for molluscum contagiosum (molluscum) in adult and pediatric patients
Mentions: VRCA
Novan craters as company files for bankruptcy, to sell most of its assets (NASDAQ:NOVN)
Novan (NOVN) shares plummeted -68.7% on Monday after the company said it had filed for bankruptcy and entered into a deal to sell most of its assets to Ligand Pharmaceuticals (LGND) for...
Mentions: LGND
Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting Thursday with a detailed look at all of the biggest pre-market stock movers worth keeping an eye on today!
Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio...
Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
Novan drops 13%, will reduce workforce by 50% (NASDAQ:NOVN)
Novan (NOVN) will restructure its commercial business, impacting 39 employees, resulting in a reduction of ~50% of employees, primarily among its field sales representatives.The...
Novan Focuses Strategic Direction and Announces Restructuring
Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update
– Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) – – Strong prescription growth across three promoted...
Novan to Report First Quarter 2023 Financial Results on May 15, 2023
DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first...
Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹
Published results from a National Psoriasis Foundation-fielded survey included responses from more than 400 patients across US1 Findings highlight...
Novan rises 12% on full-year result beat (NASDAQ:NOVN)
Novan (NOVN) is trading 12.1% higher after the company posted better-than-expected full-year result helped by strong sales of medical dermatology products. License and...
Novan Reports Full Year 2022 Financial Results and Provides Corporate Update
– Berdazimer gel, 10.3% (SB206) assigned PDUFA goal date of January 5, 2024 – – Strong year-over-year prescription growth across three promoted...